Atopic Dermatitis

A recent study showed that patients with atopic dermatitis have a higher prevalence of infertility, highlighting the need for clinicians to be wary of this increased risk and improve the care and management of this patient population.

Amy Paller, MD, sits down to answer important questions on the FDA approval of dupilumab for patients aged 6 months to 5 years.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.

A poster presented at the 2022 Fall Clinical Dermatology Conference for PAs & NPs showed normalization of skin barrier function in patients with moderate to severe atopic dermatitis taking dupilumab, according to the investigators.

Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

It's a hallmark of atopic dermatitis, but isn't always easy to assess. A presentation at the Revolutionizing Atopic Dermatitis meeting looks at available tools.

An abstract presented at the Revolutionizing Atopic Dermatitis meeting discussed the impact of treatment with dupilumab on the quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

What is the relationship between mental disorders and atopic dermatitis? Investigators from a recent study endeavored to find out.

How to prevent, minimize, and treat maskne

Irritated skin in the diaper area may make parents first think of diaper rash, but atopic dermatitis is another possible condition. Knowing the triggers can help determine the correct diagnosis.

Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children at the virtual Maui Derm MP+PA Fall 2021 conference.

Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from LIBERTY AD trial for pediatric patients ages 6 months to 5 years.

A phase 3 trial studies the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis.

A study published in the Journal of the American Academy of Dermatology examined the potential relationship between air pollution and the incidence of atopic dermatitis.

New and forthcoming options bring opportunity for optimizing patient care.

Can probiotics help with atopic dermatitis risk? A meta-analysis offers some answers.

The signs of dermatologic conditions can be different in skin of color. A report offers clinical pearls on how to examine and treat common conditions in skin of color.

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Atopic dermatitis is a chronic, inflammatory skin condition that affects 15% to 20% of children and 1% to 3% of adults in the United States. The prevalence of atopic dermatitis, which is also known as eczema, is increasing in developing and industrialized countries.

An investigation examines which infants might require screening before peanut introduction.

Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.

Atopic dermatitis treatment has dramatically changed over the years. Here’s a look at the current options.

The US Food and Drug Administration has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years.